Reporting Scenario # 5 September 18, 2005. Scenario # 5 Ms. Wright has malignant melanoma. Ms. Wright has malignant melanoma. Tumor obtained at resection.

Slides:

Advertisements

Similar presentations

Tips to a Successful Monitoring Visit

Advertisements

Building A Clinical Trial Budget The Vanderbilt Way Lynda Lane, MS, RN Administrative Director, GCRC.

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

How to Survive an FDA Inspection

What is involved? What are your responsibilities? May 2013: Research Institute, Clinical Research Administration Investigational New Drug Application (IND)

Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.

Appendix G Updates Matthew Duff Biosafety Specialist.

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.

GTP Scenario # 2 September 17,2005. Scenario # 2 Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial.

Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

CBER Irradiated Blood Components Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.

CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.

Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International

Introducing Apceden™.

Use and Care of Vertebrate Animals: What Researchers Need to Know Brian Greene IACUC Chair and Associate Professor of Biology Missouri State University.

CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.

Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.

New Faculty Orientation August 22, 2012 UAMS Research Support Center Director: Tom Wells (501)

Sara Brand Associate Director Research Compliance Administration.

Budget Development Presented by: Jean Mercer Associate Director for Clinical Research Administration Office of Clinical Research – School of Medicine.

GTP Scenario # 3 September 17,2005. Scenario # 3 A donor is to donate lymphocytes to a sibling 1 year after having been the PBPC donor. A donor is to.

Apheresis Blood Components

FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.

Safety in the Science Lab

Reporting Scenario # 1 September 18, Scenario # 1 A pancreas is used to prepare islets under IND. The donor was a victim in a motor vehicle accident.

What is Clinical Research? SEPA Skills Curriculum Cornell Note Taking SEPA Skills Curriculum Cornell Note Taking.

The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.

Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.

1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.

How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.

Problem Management Scenario # 2 September 17,2005.

Income / Education OGT Prep Week of January 28, 2013 Ms. Lynch.

RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.

1 NVAC Washington, D.C. February 3, Agenda I.Overview of Influenza Vaccine Production and Development II.Vaccine Supply/Demand: Recent Trends.

RIHES JJ: Required Training Version 7.0 Effective Date 27 JAN 2011 Boonlure Pruenglampoo 15 Jan 2014 วันพุธที่ 15 มกราคม พ. ศ 2557 RIHES-JJ Version 7.0.

Reporting Scenario # 4 September 18, Scenario # 4 Mr Brando is entered on single- arm phase I/II tiral of allogeneic unrelated donor MSCs for the.

Sponsor Visits and Monitoring

Non-compliance with Human Subjects Research Regulations J. Bruce Smith, MD, CIP November 2014 Continuing Education for IRB Members.

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.

Responsibilities of Sponsor, Investigator and Monitor

Remote Site Initiation Visits

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.

The CRT of EFS Where We’ve Been and Where We’re Going

Responsibilities of Sponsor, Investigator and Monitor

GTP Scenario # 4 September 17,2005.

Reportable Events & Other IRB Updates February 2017

Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Producing a Pharmaceutical or Biopharmaceutical

Challenges in the Development of Effective Peptide Vaccines for Cancer

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells by Susanne M. Schmidt,

QP FORUM 2018 QP DECISION MAKING.

Converting Cold into Hot Tumors by Combining Immunotherapies

Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.

Reporting Scenario # 3 September 18, 2005.

Dendritic Cell Therapies for Hematologic Malignancies

Human Gene Therapy Institutional Review Procedures

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Fig. 1 General schema for using the adoptive cell transfer of naturally occurring autologous TILs. General schema for using the adoptive cell transfer.

From Cesium to X-Ray: A Cell Therapy Perspective

Presentation transcript:

Reporting Scenario # 5 September 18, 2005

Scenario # 5 Ms. Wright has malignant melanoma. Ms. Wright has malignant melanoma. Tumor obtained at resection was banked. Tumor obtained at resection was banked. Pt is enrolled on a IND vaccination trial using auto DC pulsed with an auto tumor cell lysate. Pt is enrolled on a IND vaccination trial using auto DC pulsed with an auto tumor cell lysate. Vaccine is delivered intradermally every 2 weeks x 4. Vaccine is delivered intradermally every 2 weeks x 4.

Scenario # 5 An apheresis product is used to prepare monocytes. An apheresis product is used to prepare monocytes. Cells are cultured with IL-4 & GM- CSF in a closed system. Cells are cultured with IL-4 & GM- CSF in a closed system. Day 6, iDC are tested (sterility, endotoxin & mycoplasma). Day 6, iDC are tested (sterility, endotoxin & mycoplasma). iDC = 60% CD86+HLA-DR+ & 32% Lymphs. iDC = 60% CD86+HLA-DR+ & 32% Lymphs. iDC Spec = 70% CD86+HLA-DR+ cells (iDC do not pass spec, but process continued) iDC Spec = 70% CD86+HLA-DR+ cells (iDC do not pass spec, but process continued)

Scenario # 5 iDC are matured using IL-1ß, TNF-α, IL-6 and auto tumor lysate. iDC are matured using IL-1ß, TNF-α, IL-6 and auto tumor lysate. Final product did not meet the spec of 70% CD86+HLA-DR+mDC. Final product did not meet the spec of 70% CD86+HLA-DR+mDC. All safety tests were within spec. All safety tests were within spec. The PI is notified and decides to deliver the vaccine. The PI is notified and decides to deliver the vaccine. The lab director releases the vaccine, but starts a deviation report. The lab director releases the vaccine, but starts a deviation report.

Scenario # 5 Was the PI correct in delivering the vaccine that did not meet spec? Was the PI correct in delivering the vaccine that did not meet spec? Non-FDA response: PI was correct, because this is not a safety issue. Non-FDA response: PI was correct, because this is not a safety issue. FDA response: FDA response: Deviation from release criteria or specifications (even non-safety criteria) should be discussed with the FDA prior to administration, if possible. Deviation from release criteria or specifications (even non-safety criteria) should be discussed with the FDA prior to administration, if possible. The sponsor should report the release of the product as a protocol deviation/violation. The sponsor should report the release of the product as a protocol deviation/violation. LESSON: BE CAREFUL HOW YOU WRITE YOUR PRODUCT SPECIFICATIONS OR RELEASE CRITERIA. YOU CAN WRITE THESE AS ACTION LIMITS OR TARGETS, BUT THE FDA CONSIDERS A SPECIFICATION AS SOMETHING THAT YOU MUST MEET, OR IT IS A DEVIATION. LESSON: BE CAREFUL HOW YOU WRITE YOUR PRODUCT SPECIFICATIONS OR RELEASE CRITERIA. YOU CAN WRITE THESE AS ACTION LIMITS OR TARGETS, BUT THE FDA CONSIDERS A SPECIFICATION AS SOMETHING THAT YOU MUST MEET, OR IT IS A DEVIATION.

Scenario # 5 Should this deviation be reported to the FDA? If so, how should it be reported? Should this deviation be reported to the FDA? If so, how should it be reported? Non-FDA response: Yes, in the IND annual report. Non-FDA response: Yes, in the IND annual report. FDA response: Major deviations need to be reported in an expedited fashion. FDA response: Major deviations need to be reported in an expedited fashion.

Scenario # 5 Can the laboratory ‘improve’ the procedure by removing lymphocytes without asking the FDA permission? Can the laboratory ‘improve’ the procedure by removing lymphocytes without asking the FDA permission? Attempts to “improve” the product should not be done unless the alternative manufacturing steps have been outlined in SOPs and IND. Attempts to “improve” the product should not be done unless the alternative manufacturing steps have been outlined in SOPs and IND.